Astorne Capital decreased its stake in Senores Pharmaceuticals from 1.95% to 1.36%, selling 2,68,822 shares.
A pharmaceutical manufacturer that produces complex generic medicines certified by global regulatory authorities including the FDA and WHO. Incorporated in 2015, the company focuses on developing and supplying affordable, high-quality pharmaceutical formulations to domestic and international markets. Its operations center on manufacturing specialized generics that address critical therapeutic areas while maintaining stringent international quality standards and compliance requirements.
Astorne Capital is a Singapore-based variable capital company managed by fund manager Prosperitas Capital, investing in Indian listed and SME equities.
